Oncodesign announces EUR 10 million funding for oncology biomarker program IMAkinib
"The development will take place while we work on lead optimization programs for kinase inhibitors for our pharmaceutical customers," said Philippe Genne, Oncodesign CEO. "This synergy has the added advantage of benefiting our customers while we work on biomarkers adapted to the clinical environment and to the prescription of their therapies. IMAkinib means that Oncodesign will be clearly positioned on the drug discovery and pharmaco-imaging biomarker markets. The program will be a cornerstone of our strategy, which we started a year ago, to become a key player in therapeutic and diagnostic oncology discovery over the next three years."
The OSEO financing comes as part of France's ISI program for strategic industrial innovation (Innovation Stratégique Industrielle). ISI aims are to foster the emergence of European or global champions.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.